Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,565 shares of the company’s stock after acquiring an additional 2,644 shares during the period. Rhumbline Advisers owned about 0.10% of Apellis Pharmaceuticals worth $4,740,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in APLS. Vanguard Personalized Indexing Management LLC acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth about $281,000. Level Four Advisory Services LLC acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth about $626,000. Norges Bank acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth about $56,640,000. Assetmark Inc. raised its position in Apellis Pharmaceuticals by 52.6% during the fourth quarter. Assetmark Inc. now owns 17,344 shares of the company’s stock worth $1,038,000 after acquiring an additional 5,975 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth about $13,755,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Piper Sandler assumed coverage on shares of Apellis Pharmaceuticals in a research report on Friday, May 31st. They issued a “neutral” rating and a $46.00 price objective for the company. Jefferies Financial Group reissued a “buy” rating and issued a $80.00 price objective on shares of Apellis Pharmaceuticals in a research report on Wednesday, July 31st. Wedbush boosted their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. The Goldman Sachs Group boosted their price objective on shares of Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Wells Fargo & Company cut their price objective on shares of Apellis Pharmaceuticals from $57.00 to $48.00 and set an “equal weight” rating for the company in a research report on Thursday, May 23rd. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $71.67.

Insider Activity

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the completion of the transaction, the director now directly owns 136,998 shares in the company, valued at $5,375,801.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Price Performance

APLS opened at $37.62 on Monday. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals, Inc. has a 52-week low of $33.49 and a 52-week high of $73.80. The company has a 50 day moving average of $38.14 and a two-hundred day moving average of $44.63. The company has a market cap of $4.58 billion, a P/E ratio of -10.87 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. The business had revenue of $199.70 million during the quarter, compared to the consensus estimate of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business’s quarterly revenue was up 110.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.02) earnings per share. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.29 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).